Lympro will put AMBS on the map and the revenue will increase and stabilize share price. Don't discount MANF in the near term. Orphan Drug Designation will get the eyes and ears of BP quickly. If RP data is as good as many suggest then they will be all over it and want to partner. Breakthrough designation is not out of question either and would hope AMBS is going to submit that request.